Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 361 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bladder, Overactive Clear all
Terminated Not applicable Interventional Results available

Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence

NCT03535857
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urinary Incontinence, Urge
Interventions
PTNS
Device
Lead sponsor
Gnankang Sarah Napoe
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 23, 2026, 8:50 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Premarin Versus Toviaz for Treatment of Overactive Bladder

NCT01613170
View directory record Official record
Conditions
Overactive Bladder
Interventions
Toviaz, Premarin, Placebo cream
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
30 Years to 100 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 4 Interventional Results available

Mirabegron in Parkinson Disease and Impaired Cognition

NCT02536976
View directory record Official record
Conditions
Parkinson Disease, Overactive Bladder, Impaired Cognition
Interventions
mirabegron, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
25 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Golden Valley, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 23, 2026, 8:50 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Reduced-dose Botox for Urgency Incontinence Among Elder Females

NCT05512039
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence in Old Age, Urgency Urinary Incontinence
Interventions
Botox 50 Unit Injection, Botox 100 Unit Injection
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
70 Years and older · Female only
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • San Diego, California • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 4 Interventional Results available

Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder Symptoms

NCT00928395
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Urgent PC
Device
Lead sponsor
Uroplasty, Inc
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Chico, California • Greenwich, Connecticut • Naples, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Oct 23, 2026, 8:50 AM EDT
Withdrawn Phase 4 Interventional

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

NCT02981459
View directory record Official record
Conditions
Urinary Frequency/Urgency, Bladder Irritable, Bladder Pain Syndrome
Interventions
Mirabegron
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 89 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 23, 2026, 8:50 AM EDT
Recruiting Not applicable Interventional

At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women

NCT07178314
View directory record Official record
Conditions
Overactive Bladder
Interventions
Transcutaneous Tibial Nerve Stimulation (TTNS)
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 2 Interventional

SSR240600C Treatment in Women With Overactive Bladder

NCT00564226
View directory record Official record
Conditions
Overactive Bladder
Interventions
SSR240600C, tolterodine, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

NCT00350636
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin topical gel, Placebo topical gel
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00662909
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
109
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 100 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 23, 2026, 8:50 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Overactive Bladder Treatment Access and Adherence

NCT06094543
View directory record Official record
Conditions
Overactive Bladder Syndrome, Urinary Incontinence
Interventions
Patient Engagement Tool
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 23, 2026, 8:50 AM EDT
Terminated Phase 2 Interventional

Testing MitoQ on Lower Urinary Tract Symptoms in Older Women With Metabolic Syndrome

NCT06351683
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Overactive Bladder Syndrome
Interventions
MitoQ (mitoquinol mesylate), Placebo
Drug · Other
Lead sponsor
Iman Al-Naggar, PhD
Other
Eligibility
50 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 2 Interventional

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

NCT00220389
View directory record Official record
Conditions
Overactive Bladder
Interventions
SPM 907
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Timeline
2003 – 2007
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2008 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 4 Interventional

Lidocaine for Pain After Urodynamic Testing

NCT03390790
View directory record Official record
Conditions
Voiding Disorders, Overactive Bladder, Urinary Incontinence
Interventions
Lidocaine gel 2%, Standard lubricant gel
Drug · Other
Lead sponsor
Atlantic Health System
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Oct 23, 2026, 8:50 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

NCT01777217
View directory record Official record
Conditions
Over-Active Bladder
Interventions
Solifenacin succinate, Placebo
Drug
Lead sponsor
Advanced Research Network
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 23, 2026, 8:50 AM EDT
Terminated Phase 4 Interventional

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

NCT01092624
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex
Drug · Device
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Early Phase 1 Interventional

IVES for Treatment of UUI and OAB

NCT02992509
View directory record Official record
Conditions
Urinary Bladder, Overactive, Urinary Incontinence, Urge
Interventions
EMED detruset(TM) intravesical electrical stimulation
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

NCT03583372
View directory record Official record
Conditions
Overactive Bladder
Interventions
Vibegron, placebos, Tolterodine Tartrate ER
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
107
States / cities
Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 23, 2026, 8:50 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.

NCT00323635
View directory record Official record
Conditions
Urinary Incontinence
Interventions
tolterodine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Not applicable Interventional

High Intensity Focused Electromagnetic Field Device for Urinary Incontinence

NCT04031014
View directory record Official record
Conditions
Stress Urinary Incontinence, Urge Incontinence, Urge and Stress, Overactive Bladder
Interventions
BTL EMSELLA Active treatment, BTL EMSELLA Sham Treatment
Device
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

NCT00501267
View directory record Official record
Conditions
Overactive Bladder
Interventions
solabegron and oxybutynin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 23, 2026, 8:50 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

NCT00773552
View directory record Official record
Conditions
Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions
solifenacin succinate, placebo
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
20 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 23, 2026, 8:50 AM EDT
Completed Not applicable Interventional

Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms

NCT04758247
View directory record Official record
Conditions
Overactive Bladder
Interventions
TheraNova Neuromodulation System
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Sacramento, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 8:50 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

OAB and the Microbiome

NCT04831801
View directory record Official record
Conditions
Overactive Bladder, Urgency-frequency Syndrome
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 23, 2026, 8:50 AM EDT